- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: March 2019
- Public Summary Document (PSD) March 2019 PBAC Meeting - PDF
- Public Summary Document (PSD) March 2019 PBAC Meeting - Word
Tofacitinib – March 2019
Tofacitinib: Tablet 5 mg, Tablet 10 mg; Xeljanz®
Last updated
5 July 2019